Last Week in Healthcare Reform: June 6th, 2022
Pharmacy Benefit Managers, or PBMs, work for YOU to connect you with the right medicine, at the right time and at the right price.
Pharmacy Benefit Managers, or PBMs, work for YOU to connect you with the right medicine, at the right time and at the right price.
A new study reinforces the link between hospital prices and market share; unnecessary care is found to have persisted during the pandemic; stakeholders continue to urge for full implementation of consumer surprise medical billing protections; and, Medicare spending on prescription drugs outpaces R&D costs.
Hospitals look to historic rate increases to cover their costs; millions threatened with loss of coverage after the public health emergency ends; a reminder that drugmakers are ultimately the ones responsible for controlling insulin costs; and, stakeholders continue to defend the Medicare Advantage program.
A new report shines a light on hospital drug errors; elsewhere, trends point to broad geographic variation in hospital pricing; stakeholders rally to the defense of the critical Medicare Advantage program; and, a look at how Big Pharma exploits the patent system to its own benefit.
Access for Maine consumers threatened by hospital system; the Administration appeals a surprise medical billing court ruling; private equity continues to exert pressure on our healthcare delivery model; and, a look at how access to Medicaid impacts health equity.
An important milestone is reached for new consumer surprise medical billing protections; proposed changes to Medicare Advantage are finalized; a new study takes a look at nonprofit hospitals’ charity care; and, rising drug prices continue to leave vulnerable populations exposed.
An important milestone is reached for new consumer surprise medical billing protections; proposed changes to Medicare Advantage are finalized; a new study takes a look at nonprofit hospitals’ charity care; and, rising drug prices continue to leave vulnerable populations exposed.
Premiums in Medicare Part D plans that cap insulin costs are higher than those that don’t; audio-only telehealth continues to play a critical role in connecting patients to care; unexpected medical bills rank amongst consumers’ biggest financial worries; and, new projections provide insights into where our healthcare spending might be headed.
Stakeholders continue to urge for full implementation of consumer surprise medical billing protections; a new report seeks to clarify the relationship between PBMs and drug prices; studies link rising costs and low-value to care delivered by hospital-employed physicians; and, a focus on value-based care improves outcomes and reduces costs.
Scapegoating PBMs diverts focus away from who’s really to blame for high drug prices; meanwhile, research continues to poke holes in Big Pharma’s innovation rhetoric; a new campaign is launched highlighting the value of employer-provided health coverage; and, patients want hospitals to disclose emergency room fees.